Use of novel antithrombotic agents for COVID-19: Systematic summary of ongoing randomized controlled trials.

ABSTRACT:

Background

Coronavirus disease 2019 (COVID-19) is associated with macro- and micro-thromboses, which are triggered by endothelial cell activation, coagulopathy, and uncontrolled inflammatory response. Conventional antithrombotic agents are under assessment in dozens of randomized controlled trials (RCTs) in patients with COVID-19, with preliminary results not demonstrating benefit in several studies.

Objectives

Given the possibility that more novel agents with antithrombotic effects may have a potential utility for management of patients with COVID-19, we assessed ongoing RCTs including these agents with their potential mechanism of action in this population.

Methods

We searched clinicaltrials.gov and the World Health Organization International Clinical Trials Registr

SUBMITTER: Talasaz AH 

PROVIDER: S-EPMC8646701 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature